ProQR Net Income From Continuing Ops from 2010 to 2024
| PRQR Stock | USD 3.65 0.17 4.45% |
Net Loss | First Reported 2012-12-31 | Previous Quarter -7.7 M | Current Value -2.7 M | Quarterly Volatility 10.8 M |
Check ProQR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProQR Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Total Revenue of 6.8 M or Research Development of 30.4 M, as well as many indicators such as Price To Sales Ratio of 21.16, Dividend Yield of 0.0 or PTB Ratio of 3.68. ProQR financial statements analysis is a perfect complement when working with ProQR Therapeutics Valuation or Volatility modules.
ProQR | Net Income From Continuing Ops |
Latest ProQR Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of ProQR Therapeutics BV over the last few years. It is ProQR Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProQR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
ProQR Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (30,717,923) | |
| Coefficient Of Variation | (71.28) | |
| Mean Deviation | 17,969,272 | |
| Median | (29,121,750) | |
| Standard Deviation | 21,897,042 | |
| Sample Variance | 479.5T | |
| Range | 61.6M | |
| R-Value | (0.75) | |
| Mean Square Error | 226.7T | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | (3,667,325) | |
| Total Sum of Squares | 6712.7T |
ProQR Net Income From Continuing Ops History
About ProQR Therapeutics Financial Statements
ProQR Therapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although ProQR Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ProQR Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ProQR Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.7 M | -29.1 M |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ProQR Stock
| 0.82 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.76 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
| 0.71 | OGN | Organon | PairCorr |
| 0.66 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.66 | AZN | AstraZeneca PLC ADR | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.